Ana Carolina Campi-Azevedo

Ana Carolina Campi-Azevedo

Auto-generated profile, based on publicly available information

Ana Carolina Campi-Azevedo

Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Av. Augusto de Lima, 1715, Belo Horizonte 30190-002, Brazil

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2008 in Acta Tropica
Verified
Journal Article
Closed access
ICIramaya Rodrigues Caldas
Iramaya Rodrigues Caldas
ACAna Carolina Campi-Azevedo
Ana Carolina Campi-Azevedo
LOLucia Fraga Alves Oliveira
Lucia Fraga Alves Oliveira
ASAlda Maria Soares Silveira
Alda Maria Soares Silveira
RORodrigo C. Oliveira
Rodrigo C. Oliveira
GGGiovanni Gazzinelli
Giovanni Gazzinelli

16 August 2011 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MLMaria Luiza-Silva
Maria Luiza-Silva
ACAna Carolina Campi-Azevedo
Ana Carolina Campi-Azevedo
MBMaurício Azevedo Batista
Maurício Azevedo Batista
RARenato Sathler Avelar
Renato Sathler Avelar
DLDenise da Silveira Lemos
Denise da Silveira Lemos
OMOlindo Martins-filho
Olindo Martins-filho
Background. The live attenuated yellow fever (YF) vaccines have been available for decades and are considered highly effective and one of the safest vaccines worldwide.

15 July 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ACAna Carolina Campi-Azevedo
Ana Carolina Campi-Azevedo
PEPaula de Almeida Estevam
Paula de Almeida Estevam
JCJordana Grazziela Alves Coelho-dos-Reis
Jordana Grazziela Alves Coelho-dos-Reis
VPVanessa Peruhype-Magalhães
Vanessa Peruhype-Magalhães
GVGabriela Villela-Rezende
Gabriela Villela-Rezende
OMOlindo Martins-filho
Olindo Martins-filho
The live attenuated 17DD Yellow Fever vaccine is one of the most successful prophylactic interventions for controlling disease expansion ever designed and utilized in larger scale. However, increase on worldwide vaccine demands and manufacturing restrictions urge for more detailed dose sparing studies. The establishment of complementary biomarkers in addition to PRNT and Viremia could support a secure decision-making regarding the use of 17DD YF vaccine subdoses. The present work aimed at comparing the serum chemokine and cytokine kinetics triggered by five subdoses of 17DD YF Vaccine.

14 May 2018 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
Felipe NavecaFelipe Naveca
Felipe Naveca
GPgemilson pontes
gemilson pontes
ACAileen Yu-Hen Chang
Aileen Yu-Hen Chang
GSGeorge Allan Villarouco da Silva
George Allan Villarouco da Silva
VNValdinete Alves Do Nascimento
Valdinete Alves Do Nascimento
RRRajendranath Ramasawmy
Rajendranath Ramasawmy
Key words Zika virus; CXCL10; biomarkers; chemokines; cytokines

26 August 2015 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
ACAna Carolina Campi-Azevedo
Ana Carolina Campi-Azevedo
CCChristiane Costa-Pereira
Christiane Costa-Pereira
LALis R Antonelli
Lis R Antonelli
CFCristina T Fonseca
Cristina T Fonseca
ATAndréa Teixeira-Carvalho
Andréa Teixeira-Carvalho
OMOlindo Martins-filho
Olindo Martins-filho
A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results of vaccinees who received a single dose of 17DD-YF immunization followed over 10 y challenge this premise. YF-neutralizing antibodies, subsets of memory T and B cells as well as cytokine-producing lymphocytes were evaluated in groups of adults before (NVday0) and after (PVday30-45, PVyear1-4, PVyear5-9, PVyear10-11, PVyear12-13) 17DD-YF primary vaccination. YF-neutralizing antibodies decrease significantly from PVyear1-4 to PVyear12-13 as compared to PVday30-45, and the seropositivity rates (PRNT≥2.9Log10mIU/mL) become critical (lower than 90%) beyond PVyear5-9. YF-specific memory phenotypes (effector T-cells and classical B-cells) significantly increase at PVday30-45 as compared to naïve baseline. Moreover, these phenotypes tend to decrease at PVyear10-11 as compared to PVday30-45. Decreasing levels of TNF-α+ and IFN-γ+ produced by CD4+ and CD8+ T-cells along with increasing levels of IL-10+CD4+T-cells were characteristic of anti-YF response over time. Systems biology profiling represented by hierarchic networks revealed that while the naïve baseline is characterized by independent micro-nets, primary vaccinees displayed an imbricate network with essential role of central and effector CD8+ memory T-cell responses. Any putative limitations of this cross-sectional study will certainly be answered by the ongoing longitudinal population-based investigation. Overall, our data support the current Brazilian national immunization policy guidelines that recommend one booster dose 10 y after primary 17DD-YF vaccination.

1 January 2011 in Vaccine
Verified
Journal Article
Closed access
MSMaria Luiza Silva
Maria Luiza Silva
MMMarina Angela Martins
Marina Angela Martins
LELuçandra Ramos Espírito-Santo
Luçandra Ramos Espírito-Santo
ACAna Carolina Campi-Azevedo
Ana Carolina Campi-Azevedo
DSDenise Silveira-Lemos
Denise Silveira-Lemos
OMOlindo Martins-filho
Olindo Martins-filho